Chinese pharmaceutical companies have completed 10 overseas licensing transactions.

In January, before the end of the month, Chinese pharmaceutical companies have already completed 10 overseas licensing transactions, with the down payment for the deals between Rongchang Biotechnology and AbbVie reaching 650 million US dollars. 2025 is a big year for Chinese innovative drug overseas transactions. Industry experts interviewed by First Financial believe that this trend will continue. Huang Yang, Director of Healthcare Industry Research at J.P. Morgan Greater China, said, "The number or total amount of overseas transactions in 2026 may be difficult to surpass 2025, but the strong momentum will be maintained."